FB 811

Drug Profile

FB 811

Alternative Names: FB811; Glycosylated rituximab - Fountain Biopharma; Rituximab biobetter - Fountain Biopharma

Latest Information Update: 23 Oct 2015

Price : $50

At a glance

  • Originator Fountain BioPharma
  • Class Antineoplastics; Antirheumatics; Monoclonal antibodies
  • Mechanism of Action B cell inhibitors; CD20 antigen inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Preclinical Non-Hodgkin's lymphoma

Most Recent Events

  • 04 Sep 2015 Preclinical trials in Non-Hodgkin's lymphoma in Taiwan (IV) before September 2015
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top